FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution
Executive Summary
It didn't seem like deliberate choice to play good cop-bad cop, but Acting Office of Generic Drugs Director Keith Webber and Center for Drug Evaluation and Research Director Janet Woodcock offered a near textbook version of it at the recent Generic Pharmaceutical Association Fall Technical Conference.
You may also be interested in...
FDA Reassures Patients Of Generic Drug Quality Amid Questions In Media Analysis
Commissioner Scott Gottlieb and CDER Director Janet Woodcock say in joint statement that patients can be confident generics are safe and effective and recent media reports misinterpreted inspection and other data when suggesting the contrary.
US FDA Considers Mapping Generic Drug Complaints To Spot Safety Trends
A cluster of complaints in one area may inform a new safety signal or other problem, agency official says.
FDA Biosimilar Education Campaign Will Need To Be Targeted
Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.